Key facts
- CascadeBio’s last known valuation is $14.4M (Sep 2025).
- It has raised $5.4M; the latest was Seed Round ($5.4M) in Sep 2025.
- Notable investors include US National Science Foundation, Third Derivative, Boost VC, For ClimateTech, Spacecadet Ventures — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for CascadeBio
- ·The full record, as it builds
Funding rounds
No funding rounds for CascadeBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CascadeBio
Developer of enzyme immobilization kits designed to improve the sustainability and efficiency of existing processes of chemical manufacturing. The company offers pharmaceutical ingredient synthesis, enzyme engineering, and biosensing, along with a platform that represents a rational approach to enzyme stabilization via immobilization, enabling pharmaceutical manufacturing companies to integrate engineered enzymes in less time with reduced cost.
- Sector
- Business Products and Services (B2B)
- HQ
- Denver, CO, United States
- Founded
- 2022
- Employees
- 8
- Website
- cascadebio.com/
- Ownership
- Privately Held (backing)
CascadeBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CascadeBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CascadeBio in its N-PORT filings yet. We sweep new filings monthly.